NEW YORK and STOCKHOLM, Oct. 3, 2012 (GLOBE NEWSWIRE) -- Intellect Neurosciences, Inc. (OTCBB:ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of proteinopathies, and iNovacia, leading experts in compound screening, announced today they have entered into a Research Service Agreement to evaluate preclinical compounds for the drug optimization and selection program for Intellect’s antibody drug conjugate, CONJUMAB-A, which is being developed for age related macular degeneration (AMD).
